Compare Global E Online Ltd (GLBE) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Medpace Holdings Inc — how do they compare? Global E Online Ltd trades at $40.26 (market cap $6.75B), while Medpace Holdings Inc trades at $602 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 2.5× Global E Online Ltd's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 1,468,708). Which is the better fit depends on your goals — on Pluang, investors hold Global E Online Ltd for 21 Days and Medpace Holdings Inc for 14 Days on average.
| GLBE | MEDP | |
|---|---|---|
Market Cap | $6.75B | $16.82B |
Volume | 1,468,708 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $42.36 | $630.19 |
52-Week Low | $27.54 | $393.42 |
Typical Hold Time | 21 Days | 14 Days |
Enterprise Value | $6.24B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $38.96, up 0.67% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates, and raised its full-year 2026 outlook. Revenue grew 39% year-over-year in Q2, with an adjusted EBITDA margin expansion to 20.9%. Analyst consensus is strongly bullish with a $48.86 price target, though recent insider selling and a high P/E ratio of 45.65 warrant attention.
The outlook for GLBE is positive based on robust revenue growth and raised guidance, but risks include high valuation multiples and insider selling activity. The stock presents a growth opportunity if execution continues, yet investors should weigh the premium valuation against future earnings potential amid competitive e-commerce markets.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
